AgingResearch.NewsJoin free
Obesity Pillars

Adults with obesity reported better function on orforglipron

Patient reports from two randomized, placebo-controlled trials showed improved physical functioning over 72 weeks, while effects on psychological and social functioning varied.

Paper by Michelle Look, Harold Edward Bays, Carel Wynand le Roux, +9 more authorsChristy R. Houle · Knownwell · Eli Lilly (United States)
Graphical abstract from Obesity Pillars
Open the figure at full size
Graphical abstract. Look et al.

Our read

Interventions
Studied:
Randomized trial in people (72 weeks, placebo-controlled, registered NCT05869903)
In the record:
The 24th paper on orforglipron with results in people; 75 on record in all. Its result on body weight agrees with 22 of 23 other findings on record; 1 found no change.
Why it’s aging research:
It studies an intervention with evidence of extending healthy life.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

Adults with obesity, with or without type 2 diabetes, took part in two phase 3 randomized, placebo-controlled trials of orforglipron. Researchers used prespecified secondary analyses and additional post-hoc analyses to examine participants’ reports of health-related quality of life from the start of treatment to week 72.

Participants receiving orforglipron reported greater improvements than those receiving placebo across most questionnaire domains. Physical functioning improved consistently, while effects on psychological and social functioning varied. In exploratory analyses from ATTAIN-1, participants with higher starting body mass index—a measure relating weight to height—and those who initially reported physical limitations were more likely to report greater improvements.

Why it matters

Physical functioning is an important part of healthy aging. These analyses addressed whether weight-loss treatment also changed how adults with obesity experienced their health.

Caveats

The outcomes were self-reported, rather than objective tests of physical performance, and the subgroup analyses were exploratory. The abstract does not give the drug doses.

Where the evidence stands

Orforglipron

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 20 independent labs in 9 countries
  • 1 finding against
  • 36 trials, 1 with no results posted
  • Funder: Eli Lilly and Company
  • 31 of 76 findings with company ties
  • 35 of 36 trials sponsored by its developers

Comments

Be the first to comment.

More on Orforglipron